


FORM PTO-1390 (REV 10-94)		U.S. DEP. ENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 10242-32
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/600125	
INTERNATIONAL APPLICATION NO. PCT/CA99/00005	INTERNATIONAL FILING DATE 13 January 1999	PRIORITY DATE CLAIMED 13 January 1998	
TITLE OF INVENTION Composition Containing Propargylamine for Enhancing Cancer Therapy			
APPLICANT(S) FOR DO/EO/US R.C. Warrington, I.A. Paterson and A.A. Boulton			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) (a) <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). (b) <input checked="" type="checkbox"/> has been transmitted by the International Bureau. (c) <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) (a) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). (b) <input type="checkbox"/> have been transmitted by the International Bureau. (c) <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. (d) <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A SUBSTITUTE SPECIFICATION.</p> <p>15. <input type="checkbox"/> A CHANGE OF POWER OF ATTORNEY AND/OR ADDRESS LETTER.</p> <p>16. <input type="checkbox"/> Other items or information: - An executed Small Entity Declaration</p>			

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/600125		INTERNATIONAL APPLICATION NO. PCT/CA99/00005	ATTORNEY'S DOCKET NUMBER 10242-32																				
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO		CALCULATIONS PTO USE ONLY																					
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$700.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$770.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00																							
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$910.00																					
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$																					
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>36</td> <td>- 20 =</td> <td>x \$22.00</td> </tr> <tr> <td>Independent Claims</td> <td>4</td> <td>- 3 =</td> <td>x \$80.00</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td></td> <td>+ \$260.00</td> </tr> <tr> <td colspan="4" style="text-align: center;">TOTAL OF ABOVE CALCULATIONS =</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total Claims	36	- 20 =	x \$22.00	Independent Claims	4	- 3 =	x \$80.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	TOTAL OF ABOVE CALCULATIONS =				\$ 910.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																				
Total Claims	36	- 20 =	x \$22.00																				
Independent Claims	4	- 3 =	x \$80.00																				
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00																				
TOTAL OF ABOVE CALCULATIONS =																							
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$																					
SUBTOTAL =		\$ 910.00																					
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +		\$																					
TOTAL NATIONAL FEE =		\$																					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$																					
TOTAL FEES ENCLOSED =		\$910.00																					
		Amount to be refunded	\$																				
		charged	\$																				
a. <input checked="" type="checkbox"/> a check in the amount of \$910.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 02-2095 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2095. A duplicate copy of this sheet is enclosed.																							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																							
 Signature																							
Micheline Gravelle Name																							
40261 Registration No.																							
SEND ALL CORRESPONDENCE TO: Micheline Gravelle Bereskin & Parr Box 401, 40 King Street West Toronto, Ontario, Canada M5H 3Y2																							

09/600125

PCT

534 Rec'd PCT/PCT 12 JUL 2000

Our File No: 10242-32

BERESKIN & PARR
Box 401
40 King Street West
Toronto, Canada
M5H 3Y2



Telephone (416) 364-7311
Telecopier (416) 361-1398
Internet BERESKIN&PARR.COM
Cable ARNBEE Toronto

July 11, 2000

The Commissioner of Patents & Trademarks
Washington, D.C., U.S.A. 20231

Dear Sir:

Transmitted herewith for entry into national phase of the patent application of


Inventors: R.C. Warrington, I.A. Paterson and A.A. Boulton

For: **Composition Containing Propargylamine for Enhancing Cancer Therapy**

The following papers are enclosed:

- Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) concerning a filing under 35 U.S.C. 371.
- Preliminary Amendment.
- An unsigned Combined Declaration for Patent Application and Power of Attorney.
- The government filing fee in the amount of \$910.00 is included in our cheque No. 0899. Please charge any deficiency or credit any overpayment to our deposit account No. 02-2095. A duplicate copy of this sheet is enclosed.
- PAYMENT OF THE CLAIM FEES IS BEING DEFERRED.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 02-2095.
- Convention priority is requested based on United States Application no. 60/071,023 filed on 13 January 1998.

Respectfully submitted,



Micheline Gravelle
Registration No. 40,261